Drug Profile
Bupropion/trazodone
Alternative Names: Lorexys; Orexa; S1P-104; S1P-205; SIP-104; Trazodone/bupropionLatest Information Update: 27 Sep 2021
Price :
$50
*
At a glance
- Originator S1 Pharmaceuticals
- Developer S1 Biopharma
- Class Erectile dysfunction therapies; Piperazines; Propiophenones; Pyridones; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Alpha adrenergic receptor agonists; Dopamine uptake inhibitors; Serotonin 2A receptor antagonists; Serotonin 2C receptor antagonists; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Sexual function disorders
Highest Development Phases
- Phase II Erectile dysfunction; Female sexual dysfunction
- No development reported Male sexual dysfunction
Most Recent Events
- 27 Sep 2021 Bupropion/trazodone is still in phase IIb trial for Female sexual dysfunction in USA (S1 Biopharma pipeline, September 2021)
- 27 Sep 2021 Phase-II clinical trials in Erectile dysfunction (PO) (S1 Biopharma pipeline, September 2021)
- 20 Dec 2018 S1 Biopharma has patent protection for Bupropion/trazodone (Lorexys™) in Asia and Europe